The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Cone rod dystrophy is a rare inherited retinal disorder impacting cones and rods, leading to progressive vision loss. The market for cone rod dystrophy is poised for growth due to rising disease ...

Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal ...

Unfortunately, I have been diagnosed many years back with Retinal Dystrophy ( genetic mutation ). The condition has no ...

Opus Genetics has dosed the first subject in its Phase I/II clinical trial of OPGx-Best1 gene therapy for the treatment of ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

The gene therapy market for ocular rare diseases is expanding rapidly as breakthroughs in viral vectors (like AAV) and gene-editing tools enable one-time, disease-modifying treatments for previously ...

A recent review published in Genes & Diseases by researchers from the Naval Medical University and the 922nd Hospital of the Joint Service Support Force of the PLA provides a comprehensive overview of ...

Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated ...

To date in the Phase 1/2 portion of the trial, six late-stage participants have been treated with OPGx-LCA5, and all six have experienced clinically meaningful improvements in vision, providing ...

Entered into broad strategic collaboration with Eli Lilly and Company ('Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment ...

REGENXBIO posts strong Q3 results and pipeline progress. Key PDUFA catalyst ahead for investors. Read here for more on RGNX stock.